Lightbridge announces Framatome receipt of US Department of

New Post Public Reply Private Reply Replies (0) Message Board
nlightn
480
Lightbridge announces Framatome receipt of US Department of Energy GAIN voucher to support development of Lightbridge Fuel™
Thu May 30, 2019

RESTON, Va., May 30, 2019 (GLOBE NEWSWIRE) -- Lightbridge Corporation (LTBR), a nuclear fuel technology development company, today announced that Framatome received a voucher from the U.S. Department of Energy’s (DOE) Gateway (GTW) for Accelerated Innovation in Nuclear (GAIN) program to support development of Lightbridge Fuel™ in collaboration with Idaho National Laboratory (INL). This is Framatome’s third GAIN voucher and its first supporting the Lightbridge Fuel design conducted by Enfission LLC, the joint venture between Framatome and Lightbridge Corporation.

“This voucher enables Framatome to apply focused attention on key licensing steps to commercialize Lightbridge Fuel,” said Robert Freeman, vice president, Contracts and Services, Fuel Commercial and Customer Center at Framatome. “We are enthusiastic about the transformative science and technology benefits of this metallic fuel’s unique composition and geometry for the nuclear energy industry.”

Framatome’s collaboration with INL under this GAIN voucher will leverage the laboratory’s experience in fuel and material development, as well as its performance knowledge, to facilitate Framatome’s understanding of phenomena unique to uranium-zirconium metallic fuel. Over a period of 12 months, Framatome and INL will work under the voucher to generate Failure Modes and Effects Analysis (FMEA) and a Phenomena Identification Ranking Table (PIRT) based on the Lightbridge Fuel concept. Both the FMEA and PIRT are important steps in licensing an advanced fuel product in the U.S. and will be required inputs to the U.S. Nuclear Regulatory Commission.

For this work DOE will fund INL at a value of $477,000.

Seth Grae, Chief Executive Officer of Enfission, stated, “We appreciate this support from DOE for Lightbridge Fuel, which is designed to increase power output, enhance economics and provide additional safety benefits for existing and future reactors worldwide. We look forward to working closely with Framatome, INL and DOE to further advance Lightbridge Fuel toward commercialization.”

Framatome and Lightbridge (LTBG) launched the 50-50 joint venture company, Enfission, in January 2018 to develop, license and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property.

About Framatome

Framatome is a major international player in the nuclear energy market recognized for its innovative solutions and value-added technologies for designing, building, maintaining, and advancing the global nuclear fleet. The company designs, manufactures and installs components, fuel and instrumentation and control systems for nuclear power plants and offers a full range of reactor services.

With 14,000 employees worldwide, every day Framatome’s expertise helps its customers improve the safety and performance of their nuclear plants and achieve their economic and societal goals.

Framatome is owned by the EDF Group (75.5%), Mitsubishi Heavy Industries (MHI – 19.5%) and Assystem (5%)

About Lightbridge Corporation

Lightbridge (NASDAQ: LTBR) is a nuclear fuel technology development company based in Reston, Virginia, USA. The Company develops proprietary next generation nuclear fuel technologies for current and future reactors, which significantly enhances the economics and safety of nuclear power, operating about 1000° C cooler than standard fuel. In January 2018, Lightbridge and Framatome, Inc. formed a 50-50 joint venture, Enfission, LLC, to develop, license, manufacture, and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. Enfission has the exclusive rights to this technology and is responsible for the development of manufacturing processes and fuel assembly designs for pressurized water reactors (PWRs), boiling water reactors (BWRs), water-cooled small modular reactors, and water-cooled research reactors developed around this intellectual property. PWRs and BWRs constitute the most widely used reactor types in the world. Four large electric utilities that generate about half the nuclear power in the US already advise Lightbridge on fuel development and deployment. In addition to distributions from Enfission based on the parties’ ownership interest in the joint venture, Lightbridge anticipates receiving future licensing revenues in connection with sales by Enfission of nuclear fuel incorporating its intellectual property. Lightbridge also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at http://ir.ltbridge.com/alerts.cfm .

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Investor Relations Contact:

David Waldman/Natalya Rudman
Tel. +1 855-379-9900
ir@ltbridge.com

https://seekingalpha.com/pr/17528582-lightbri...evelopment
Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading